Corden Pharma GmbH
Corden Pharma GmbH, a leading contract development and manufacturing organisation (CDMO), is headquartered in Germany and operates across multiple regions, including Europe and North America. Founded in 2006, the company has established itself in the pharmaceutical and biotechnology sectors, specialising in the development and production of complex drug formulations, including injectables and oral solid dosage forms. Corden Pharma is renowned for its comprehensive range of services, from early-stage development to commercial manufacturing, with a strong emphasis on quality and regulatory compliance. The company’s unique capabilities in active pharmaceutical ingredient (API) production and advanced drug delivery systems position it as a trusted partner for clients seeking innovative solutions. With a commitment to excellence, Corden Pharma has achieved significant milestones, solidifying its market position as a preferred CDMO for global pharmaceutical companies.
DitchCarbon Score
How does Corden Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Corden Pharma GmbH's score of 38 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Corden Pharma GmbH's reported carbon emissions
Corden Pharma GmbH, headquartered in Germany, has set ambitious climate commitments aimed at significantly reducing its carbon emissions. Although specific emissions data for the most recent year is not available, the company has established near-term targets to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 55% by 2033, using 2023 as the base year. This commitment is aligned with the Science Based Targets initiative (SBTi) and reflects a proactive approach to climate action. In addition to its direct emissions reduction goals, Corden Pharma aims for 72% of its suppliers, measured by emissions from purchased goods and services, capital goods, fuel- and energy-related activities, upstream transportation and distribution, and waste generated in operations, to have science-based targets by 2029. This comprehensive strategy underscores the company's commitment to not only addressing its own emissions but also influencing its supply chain towards sustainability. Corden Pharma is also a member of the Business Ambition for 1.5°C initiative, reinforcing its dedication to limiting global warming to 1.5°C. The company has committed to achieving net-zero emissions across all scopes by 2050, further demonstrating its long-term vision for climate responsibility. Overall, Corden Pharma GmbH is taking significant steps to mitigate its environmental impact through robust emissions reduction targets and supplier engagement, positioning itself as a responsible player in the pharmaceuticals, biotechnology, and life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Corden Pharma GmbH is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
